Application | Comment | Organism |
---|---|---|
pharmacology | sphingomyelin synthase 2 (SMS2) is a potential therapeutic target for obesity and insulin resistance | Mus musculus |
Cloned (Comment) | Organism |
---|---|
gene Sgms2, relative real-time PCR expression analysis | Mus musculus |
Protein Variants | Comment | Organism |
---|---|---|
additional information | generation of SMS2 KO mice | Mus musculus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
a ceramide + a phosphatidylcholine | Mus musculus | - |
a sphingomyelin + a 1,2-diacyl-sn-glycerol | - |
? | |
a ceramide + a phosphatidylcholine | Mus musculus C57BL/6N | - |
a sphingomyelin + a 1,2-diacyl-sn-glycerol | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | Q9D4B1 | - |
- |
Mus musculus C57BL/6N | Q9D4B1 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
liver | - |
Mus musculus | - |
skeletal muscle | - |
Mus musculus | - |
white adipose tissue | - |
Mus musculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
a ceramide + a phosphatidylcholine | - |
Mus musculus | a sphingomyelin + a 1,2-diacyl-sn-glycerol | - |
? | |
a ceramide + a phosphatidylcholine | - |
Mus musculus C57BL/6N | a sphingomyelin + a 1,2-diacyl-sn-glycerol | - |
? |
Synonyms | Comment | Organism |
---|---|---|
Sgms2 | - |
Mus musculus |
SMS2 | - |
Mus musculus |
sphingomyelin synthase 2 | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
malfunction | glucose kinetics study using the radiolabeled glucose analog 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG), in wild-type (WT) and SMS2 knockout (KO) mice: insulin signaling is enhanced in the liver, white adipose tissue and skeletal muscle of SMS2 KO mice compared with those of wild-type mice. In addition, compared with in wild-type mice, blood clearance of 18F-FDG is accelerated in SMS2 KO mice when they are fed either a normal or a high fat diet. 18F-FDG uptake is also increased in insulin-targeted tissues such as skeletal muscle in the SMS2 KO mice, whereas skeletal muscle sphingolipid content is not clearly affected. Plasma levels of very long-chain fatty acid (VLCFA)-containing ceramides are markedly increased in SMS2 KO mice compared with in wild-type mice. Genetic inhibition of SMS2 elevates glucose clearance through activation of glucose uptake into insulin-targeted tissues such as skeletal muscle by a mechanism independent of hepatic SMS2. This occurs, at least in part, via indirect mechanisms such as elevation of VLCFA-containing ceramides | Mus musculus |
physiological function | role of sphingomyelin synthase 2 in glucose metabolism in whole-body and peripheral tissues in mice | Mus musculus |